Startseite>>Signaling Pathways>> Others>>(1R,2R)-2-PCCA(hydrochloride)

(1R,2R)-2-PCCA(hydrochloride)

Katalog-Nr.GC30855

(1R,2R)-2-PCCA(Hydrochlorid) ist ein Diastereomer von 2-PCCA und wirkt als potenter GPR88-Rezeptoragonist mit einem EC50-Wert von 3 nM im zellfreien Assay und 603 nM im Zellassay.

Products are for research use only. Not for human use. We do not sell to patients.

(1R,2R)-2-PCCA(hydrochloride) Chemische Struktur

Cas No.: 1609563-71-4

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
270,00 $
Auf Lager
5mg
232,00 $
Auf Lager
10mg
417,00 $
Auf Lager
25mg
834,00 $
Auf Lager
50mg
1.298,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

(1R,2R)-2-PCCA hydrochloride is a diastereomer of 2-PCCA, and acts as a potent GPR88 receptor agonist, with an EC50 of 3 nM.

(1R,2R)-2-PCCA hydrochloride is a potent GPR88 receptor agonist, with an EC50 of 3 nM[1]. (1R,2R)-2-PCCA inhibits GPR88-mediated cAMP production through a Gαi-coupled pathway, with an EC50 of 56 nM in HEK293 cells stably expressing the human GPR88 receptor and the GloSensor-22F cAMP construct[2].

[1]. Bi, Yingzhi, et al. Modulators of G Protein-Coupled Receptor 88. US 20110251204 A1. [2]. Jin C, et al. Effect of Substitution on the Aniline Moiety of the GPR88 Agonist 2-PCCA: Synthesis, Structure-Activity Relationships, and Molecular Modeling Studies. ACS Chem Neurosci. 2016 Oct 19;7(10):1418-1432.

Bewertungen

Review for (1R,2R)-2-PCCA(hydrochloride)

Average Rating: 5 ★★★★★ (Based on Reviews and 40 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for (1R,2R)-2-PCCA(hydrochloride)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.